Financial Data and Key Metrics Changes - Revenues increased approximately 13% year over year to $55.1 million, driven largely by the MindBody GLP-1 System [5] - Adjusted EBITDA of $4.8 million was flat versus last year's fourth quarter, with adjusted non-GAAP net income of $2.3 million, or $0.17 per fully diluted share [17][18] - Gross margin expanded by 40 basis points to 79.9% compared to the prior year period, primarily due to lower shipping costs and a favorable product mix [16] Business Line Data and Key Metrics Changes - Revenue in the Americas region increased 14% to $43.5 million, benefiting from the success of the MindBody GLP-1 System [15] - Active accounts in the Americas were up 6%, with increases in both consultants and customers [6] - Revenue in Asia-Pacific/Europe increased by 7.6% to $11.6 million, reflecting the positive impact of the international MindBody rollout [16] Market Data and Key Metrics Changes - The international business returned to growth for the first time in 12 quarters, with revenues in Asia-Pacific/Europe increasing by 8% [5] - The global gut health supplement market is projected to grow from $14.4 billion in 2025 to $32.4 billion by 2035, with a CAGR of 8.4% [7][8] Company Strategy and Development Direction - The company announced a definitive agreement to acquire LoveBiome, which focuses on microbiome health, enhancing its product portfolio and market presence [6][10] - The partnership with LoveBiome aims to accelerate growth through cross-selling opportunities and operational leverage [9][10] - The company is committed to modernizing its technology and marketing stack through a partnership with Shopify to enhance consumer experience [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver sustainable long-term value, supported by the successful rollout of the MindBody GLP-1 System and the LoveBiome acquisition [15] - The outlook for fiscal 2026 anticipates full-year revenue in the range of $225 million to $240 million, with adjusted non-GAAP EBITDA expected between $23 million and $26 million [20] Other Important Information - The company repurchased approximately 160,000 shares during the fourth quarter at an average price of $12.74 per share [19] - A quarterly cash dividend of $0.04 per share was announced, totaling approximately $600,000 [19] Q&A Session Summary Question: What caused the disconnect in fourth quarter revenue expectations? - Management noted that the U.S. experienced some softness due to seasonality impacts, while international numbers remained strong [22][23] Question: How much of the fiscal 2026 growth will come from LoveBiome versus organic growth? - Management indicated that the integration of LoveBiome is still being assessed, with a modest amount of revenue expected from the acquisition [23] Question: Can you provide details on LoveBiome's sales and consultant numbers? - Management refrained from disclosing specific revenue metrics or consultant numbers for LoveBiome at this time [24] Question: What is the market position of LoveBiome? - LoveBiome is a relatively young company, established in 2022, with a focus on gut microbiome health [26][29] Question: How does P84 compare to existing products? - P84 is marketed as a comprehensive product focused on the microbiome, complementing existing prebiotic and probiotic offerings [34]